CDK4 and breast cancer: Based on the clinical success of therapeutically approved CDK4/6i in HR+/HER2− metastatic BC and on encouraging preclinical results, several new selective CDK4/6i are currently being investigated to treat BC (Table 1), as recently reviewed [49,63].